Browsing Tag
CASGEVY
2 posts
Intellia’s Nexiguran Ziclumeran (nex-z) phase 3 trials paused following grade 4 liver toxicity event
Find out why Intellia Therapeutics paused its phase 3 Nexiguran Ziclumeran (nex-z) trials after a severe liver event—and what it means for CRISPR’s future.
October 27, 2025
FDA approves Vertex and CRISPR Therapeutics’ CASGEVY for sickle cell disease
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics have announced a significant milestone in medical science with the U.S. Food…
December 9, 2023